全文获取类型
收费全文 | 299087篇 |
免费 | 18670篇 |
国内免费 | 7321篇 |
专业分类
耳鼻咽喉 | 3264篇 |
儿科学 | 10767篇 |
妇产科学 | 4429篇 |
基础医学 | 22535篇 |
口腔科学 | 5550篇 |
临床医学 | 40731篇 |
内科学 | 44735篇 |
皮肤病学 | 3412篇 |
神经病学 | 16492篇 |
特种医学 | 13265篇 |
外国民族医学 | 23篇 |
外科学 | 38349篇 |
综合类 | 31414篇 |
现状与发展 | 33篇 |
一般理论 | 10篇 |
预防医学 | 35812篇 |
眼科学 | 5058篇 |
药学 | 30242篇 |
236篇 | |
中国医学 | 6294篇 |
肿瘤学 | 12427篇 |
出版年
2023年 | 3271篇 |
2022年 | 5680篇 |
2021年 | 12238篇 |
2020年 | 9362篇 |
2019年 | 13876篇 |
2018年 | 8312篇 |
2017年 | 7784篇 |
2016年 | 9916篇 |
2015年 | 12703篇 |
2014年 | 24195篇 |
2013年 | 22193篇 |
2012年 | 24616篇 |
2011年 | 21323篇 |
2010年 | 19197篇 |
2009年 | 18153篇 |
2008年 | 16767篇 |
2007年 | 16442篇 |
2006年 | 14022篇 |
2005年 | 9684篇 |
2004年 | 5786篇 |
2003年 | 4927篇 |
2002年 | 3820篇 |
2001年 | 3100篇 |
2000年 | 2709篇 |
1999年 | 1818篇 |
1998年 | 2149篇 |
1997年 | 1857篇 |
1996年 | 1625篇 |
1995年 | 1684篇 |
1994年 | 1575篇 |
1993年 | 1277篇 |
1992年 | 1439篇 |
1991年 | 1298篇 |
1990年 | 1311篇 |
1989年 | 1218篇 |
1988年 | 1124篇 |
1987年 | 999篇 |
1986年 | 861篇 |
1985年 | 1825篇 |
1984年 | 1948篇 |
1983年 | 1394篇 |
1982年 | 1447篇 |
1981年 | 1469篇 |
1980年 | 1274篇 |
1979年 | 1058篇 |
1978年 | 830篇 |
1977年 | 796篇 |
1976年 | 709篇 |
1975年 | 448篇 |
1974年 | 467篇 |
排序方式: 共有10000条查询结果,搜索用时 245 毫秒
101.
102.
通过网络调查和内容分析,从服务对象、服务内容、人员配置和服务设施等方面对纽约大学图书馆可重复性研究支持服务进行调研分析,并在此基础上总结其服务特点,提出研究型图书馆应积极应对研究领域的“可重复性危机”,倡导开放科学和可重复性研究,加强基础设施建设和开发应用软件,开展嵌入科研过程的可重复性研究培训和咨询,以期为提升研究的可重复性做出贡献。 相似文献
103.
The research and development of penicillin started with difficulty before 1949 and achieved certain results. In 1951, after the founding of the People's Republic of China, Zhang Weishen, as the only Chinese scientist who had been trained and worked in a penicillin research and development center in the United States for many years, overcame many difficulties and returned to China. In 1953, with the efforts of Zhang Weishen and his colleagues, China realized the industrialized production of penicillin, alleviating the urgent needs of the masses. Antibiotics has also become the first discipline to achieve major scientific and technological achievements after the founding of the New China. In the mid-1950s, the technical breakthrough in the localization of lactose substitutes marked the localization of the raw materials of the penicillin-producing culture medium, which paved the way for the industrialized production of penicillin with Chinese characteristics. Antibiotics have become one of the most widely used and affordable drugs for hundreds of millions of patients in China, and China has since ended the humiliating history of the “Sick Man of East Asia". 相似文献
104.
105.
《Vaccine》2022,40(33):4748-4763
This work identifies the innovations that made it possible for the Bio-Manguinhos/Fiocruz Immunobiological Technology Institute to engage in the entire production of the Oxford/AstraZeneca vaccine (ChAdOx1 nCov-19) in Brazil, just 1.8 years after the COVID-19 pandemic was declared. The results were summarized in a case-based innovation model composed of 11 workstreams, 32 stages, 22 gates, 11 innovations, and 38 events. In terms of research contributions, three were found: (i) the identification of firm and government-level innovations allowing the substantial reduction in the COVID-19 vaccine time-to-market in Brazil; (ii) the presentation of empirical evidence supporting the new Outbreak Paradigm for vaccine research, development, and production; and (iii) the proposition of a conceptual model for describing innovations through the vaccine value chain in pandemic contexts, particularly when technology transfer is involved. 相似文献
106.
107.
以华中科技大学同济医学院附属同济医院为例,探讨医院通过健全POCT管理体系,并借助信息平台改进POCT管理的经验,为其他医院POCT规范化管理提供参考。该医院通过搭建POCT管理平台,实现了设备标准化准入、人员资质统一授权、设备自动化质控和诊疗全流程闭环管理;基于信息平台的POCT管理改进,提升了医护人员的POCT认知度和操作水平,提高了医疗工作效率;实行诊疗全程风险管控,保障了医疗安全。 相似文献
108.
《Vaccine》2022,40(24):3320-3329
BackgroundCurrently, booster dose is needed after 2 doses of non-live COVID-19 vaccine. With limited resources and shortage of COVID-19 vaccines, intradermal(ID) administration might be a potential dose-sparing strategy.ObjectiveTo determine immunologic response and reactogenicity of ID ChAdOx1 nCoV-19 vaccine (AZD1222,Oxford/AstraZeneca) as a booster dose after completion of 2-dose CoronaVac(SV) in healthy adult.MethodsThis is a prospective cohort study of adult aged 18–59 years who received 2-dose SV at 14–35 days apart for more than 2 months. Participants received ID AZD1222 at fractional low dose(1×1010 viral particles,0.1 ml). Antibody responses were evaluated by surrogate virus neutralization test(sVNT) against delta variant and wild type, and anti-spike-receptor-binding-domain immunoglobulin G(anti-S-RBD IgG) at prior, day14, 28, 90, and 180 post booster. Solicited reactogenicity was collected for 7 days post-booster. Primary endpoint was the differences of sVNT against delta strain ≥ 80% inhibition at day14 and 90 compared with the parallel cohort study of 0.5-ml intramuscular(IM) route.ResultsFrom August2021, 100 adults with median age of 46 years(IQR 41–52) participated. Prior to booster, geometric mean(GM) of sVNT against delta strain was 22.4% inhibition(95 %CI 18.7–26.9) and of anti-S-RBD IgG was 109.3 BAU/ml(95.4–125.1). Post ID booster, GMs of sVNT against delta strain were 95.5% inhibition (95%CI 94.2–96.8) at day14, 73.1% inhibition (66.7–80.2) at day90, and 22.7% inhibition (14.9–34.6) at day180. The differences of proportion of participants achieving sVNT against delta strain ≥ 80% inhibition in ID recipients versus IM were + 4.2% (95 %CI -2.0to10.5) at day14, and ?37.3%(-54.2to-20.3) at day90. Anti-S-RBD IgG GMs were 2037.1 BAU/ml (95%CI 1770.9–2343.2) at day14 and 744.6 BAU/ml(650.1–852.9) at day90, respectively. Geometric mean ratios(GMRs) of anti-S-RBD IgG were 0.99(0.83–1.20) at day14, and 0.82(0.66–1.02) at day90. Only 18% reported feverish, compared with 37% of IM (p = 0.003). Common reactogenicity was erythema at injection site(53%) while 7% reported blister.ConclusionLow-dose ID AZD1222 booster enhanced lower neutralizing antibodies at 3 months compared with IM route. Less systemic reactogenicity occurred, but higher local reactogenicity. 相似文献
109.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献